Literature DB >> 30191006

Surgical treatment of hepatocellular carcinoma: should resection be performed according to Barcelona Clinic Liver Cancer classification?

Josep Fuster1,2,3,4,5,6,1,2,3,4,5,6.   

Abstract

The best results in surgical resection are obtained in patients with solitary tumors without clinically significant portal hypertension (hepatic venous pressure gradient >10 mmHg). In such settings, 5-year survival rates exceed 70%. When portal hypertension exceeds this cut-off value, 5-year survival decreases to 55%, as is also the case in patients with more than one nodule. Surgery may be technically feasible, in other words, with acceptable 30-day mortalities although the clinically relevant survival outcome is significantly reduced. In such instances, patients may be better served by liver transplantation. If this option is not available, the outcome may not differ to that obtained by ablation for small solitary hepatocellular carcinoma or for chemoembolization for those patients with multifocal hepatocellular carcinoma within the Milan criteria. This philosophy is the backbone for the Barcelona Clinic Liver Cancer decision-making process.

Entities:  

Keywords:  BCLC classification; HVPG; Milan criteria; expanded criteria; hepatocellular carcinoma; liver resection; liver transplantation; portal hypertension; vascular invasion

Year:  2015        PMID: 30191006      PMCID: PMC6095418          DOI: 10.2217/hep.15.18

Source DB:  PubMed          Journal:  Hepat Oncol        ISSN: 2045-0923


  63 in total

1.  Cancer of the Liver Italian Program (CLIP) score for staging hepatocellular carcinoma.

Authors:  Bruno Daniele; Mena Annunziata; Emiddio Barletta; Vincenza Tinessa; Massimo Di Maio
Journal:  Hepatol Res       Date:  2007-09       Impact factor: 4.288

2.  A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma.

Authors:  Wei-Ping Zhou; Eric C H Lai; Ai-Jun Li; Si-Yuan Fu; Jian-Ping Zhou; Ze-Ya Pan; Wan Yee Lau; Meng-Chao Wu
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

3.  If portal hypertension predicts outcome in cirrhosis, why should this not be the case after surgical resection?

Authors:  María Reig; Annalisa Berzigotti; Jordi Bruix
Journal:  Liver Int       Date:  2013-11       Impact factor: 5.828

4.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

5.  Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis.

Authors:  Annalisa Berzigotti; Susana Seijo; Umberto Arena; Juan G Abraldes; Francesco Vizzutti; Juan Carlos García-Pagán; Massimo Pinzani; Jaime Bosch
Journal:  Gastroenterology       Date:  2012-10-08       Impact factor: 22.682

6.  Staging for hepatocellular carcinoma: complex and confusing.

Authors:  Morris Sherman
Journal:  Gastroenterology       Date:  2014-04-26       Impact factor: 22.682

7.  Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.

Authors:  Li-Tzong Chen; Miin-Fu Chen; Lung-An Li; Po-Huang Lee; Long-Bin Jeng; Deng-Yn Lin; Cheng-Chung Wu; King-Tong Mok; Chao-Long Chen; Wei-Chen Lee; Gar-Yang Chau; Yaw-Sen Chen; Wing-Yui Lui; Chin-Fu Hsiao; Jacqueline Whang-Peng; Pei-Jer Chen
Journal:  Ann Surg       Date:  2012-01       Impact factor: 12.969

Review 8.  The model for end-stage liver disease (MELD).

Authors:  Patrick S Kamath; W Ray Kim
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

Review 9.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

10.  Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.

Authors:  Takeaki Ishizawa; Kiyoshi Hasegawa; Taku Aoki; Michiro Takahashi; Yosuke Inoue; Keiji Sano; Hiroshi Imamura; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  Gastroenterology       Date:  2008-03-08       Impact factor: 22.682

View more
  1 in total

1.  Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis.

Authors:  Lan-Qing Yao; Zheng-Liang Chen; Zi-Han Feng; Yong-Kang Diao; Chao Li; Hai-Ying Sun; Jian-Hong Zhong; Ting-Hao Chen; Wei-Min Gu; Ya-Hao Zhou; Wan-Guang Zhang; Hong Wang; Yong-Yi Zeng; Han Wu; Ming-Da Wang; Xin-Fei Xu; Timothy M Pawlik; Wan Yee Lau; Feng Shen; Tian Yang
Journal:  Ann Surg Oncol       Date:  2022-02-22       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.